3rd Feb 2021 14:14
(Alliance News) - The Swiss regulatory authority said Wednesday that data submitted by AstraZeneca PLC were not sufficient for it to authorise use of the Anglo-Swedish firm's Covid vaccine, saying "new studies" were needed.
"The data currently available do not point to a positive decision regarding benefits and risks," Swissmedic said in a statement.
"To obtain a conclusive assessment, the applicant will among other things have to submit additional efficacy data from a Phase III trial under way in North and South America, and these will have to be analysed."
AstraZeneca shares were 0.1% lower at 7,370.00 pence each in London on Wednesday afternoon.
source: AFP
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca